
News|Videos|August 31, 2023
POLARIX: Frontline Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by expert Jonathan Friedberg, MD, MMSc, to review data with frontline polatuzumab vedotin in DLBCL from the phase 3 POLARIX trial.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
4
First Patient Is Dosed in Trial of HLX-4310 for Relapsed/Refractory Osteosarcoma
5































